Trial Profile

A Phase 2a proof-of concept clinical trial of MET642 for the treatment of Ulcerative colitis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 11 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MET 642 (Primary)
Indications Ulcerative colitis
Focus Proof of concept; Therapeutic Use
Sponsors Metacrine

Most Recent Events

06 Dec 2023 According to Organovo Holdings media release, company is planning enrollment in 1H 2024, with targeted completion in 1H 2025.
13 Nov 2023 According to Organovo Holdings media release, the read out from this trial expected in 1H 2025.
12 May 2022 According to Metacrine media release, as the company assesses potential strategic alternatives, they have delayed clinical development efforts related to this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com